Multiplex biomarker assays perform better than single cancer biomarkers

First published:

Last Edited:

Number of edits:

The entire field of extracellular vesicle research is at a complexity-crossroads. Size, stiffness, charge, molecular composition, cargo molecules, they all seem to overlap between healthy and non-healthy patients, between EVs and non-EVs (see, for example: HIV-1 contains CD9 and CD63).

The only way to move one step forward is, therefore, to create multi-parametric studies on EV's. However, I have the feeling that it is not enough to study different dimensions, but that they must be done on the same particle. It will not be enough to measure size on one device, and to proteomics later.

The question is what would bring the highest yield. For example, the use of Extracellular vesicles as markers for prostate cancer has been relatively swamped, even if prostate cancer is not a minor health issue in the world.

The secret may be to identify, after doing a careful desk-research, what are the different approaches that may yield the most accurate results. What combination of parameters can be used to rule out/in a given disease, or to quantify the risk group.


These are the other notes that link to this one.


Join my experiment of better thinking and interesting discussions
Aquiles Carattino
Aquiles Carattino
This note you are reading is part of my digital garden. Follow the links to learn more, and remember that these notes evolve over time. After all, this website is not a blog.
© 2021 Aquiles Carattino
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
Privacy Policy